Following up on our recent white paper, Biopharma’s COVID Capital Comeback, here is a look at the greatest risk facing public biopharma companies — single asset failures — and what they can do during this time of robust capital.
Heading into 2020, biopharma looked like it would be typecast in its typical election year role: the big business scapegoat for everything that’s wrong in health care. There had been the usual big Phase 3 trial failures.
Biotech companies are attracted to licensing deals for a variety of important reasons: 1) to provide an alternative source of capital from the licensee to fund R&D and commercial operations including,
Besides calling the Ghostbusters, how does one catch a ghost? That is the question asked by most life science companies trying to raise capital from family offices
For many years, the fundraising environment for MedTech companies has been exceedingly difficult. Venture firms that were historically active in MedTech shifted their investment allocations to other areas of life sciences and capital became constrained.
As an early advocate for the importance of the family office in the biotech financing landscape, I have learned from recent experience what many entrepreneurs already know. Raising money from family offices is hard.
Five Tips to Successfully Raise Family Office Capital CATEGORIES Asian Capabilities Capital Raising Commercial Assessment Locust Walk Institute Market Trends
5 Mistakes an Entrepreneur Makes When Raising Capital CATEGORIES Asian Capabilities Capital Raising Commercial Assessment Locust Walk Institute Market Trends